Stockholm — August 21, 2025 — Leads & Copy — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will release its second-quarter report for April-June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.
The company invites investors, analysts, and media to an audiocast with teleconference (in English) on August 28, at 09:30 CET. CEO Gunilla Osswald, CFO Anders Martin-Löf, and colleagues will present and comment on the report, followed by a Q&A session.
Participants can join via webcast at https://bioarctic.events.inderes.com/q2-report-2025/register, where they can submit written questions. To join via teleconference, register at https://events.inderes.com/bioarctic/q2-report-2025/dial-in to receive phone numbers and a conference ID for verbal questions.
The webcast will be available on demand at BioArctic’s website after the presentation.
Oskar Bosson, VP Communications and Investor Relations, can be reached at oskar.bosson@bioarctic.com or + 46 704 10 71 80 for more information.
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments for neurodegenerative diseases. It invented Leqembi® (lecanemab), a drug proven to slow Alzheimer’s progression and reduce cognitive impairment, developed with Eisai. BioArctic has a broad research portfolio with antibodies against Parkinson’s and ALS, and utilizes its BrainTransporter™ technology. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap.
Source: BioArctic AB
